GnRH-a long regimen and antagonist regimen in PCOS patients
-
摘要:
目的比较GnRH-a长方案与拮抗剂方案在多囊卵巢综合征(PCOS)患者中的临床疗效与安全性,为临床PCOS患者合理选用超促排卵方案提供依据。 方法选择240例需要进行控制性超促排卵治疗的PCOS患者为研究对象,随机分为2组,每组120例,A组采用GnRH-a长方案,B组采用拮抗剂方案。比较两组患者的临床结局。 结果拮抗剂组患者的获卵数及人绒毛膜促性腺激素日雌激素水平低于GnRH-a长方案组,差异具有统计学意义(P<0.05),但其Gn总剂量与启动剂量低于GnRH-a长方案组(P<0.01),两组患者的优质胚胎率、妊娠率等临床结局差异无统计学意义(P>0.05)。安全性方面,拮抗剂组患者卵巢过度刺激综合征发生率及周期取消率低于GnRH-a长方案组,差异具有统计学意义(P<0.05)。 结论拮抗剂超促排卵方案与GnRH-a长方案的妊娠结局无明显差异,拮抗剂组患者卵巢过度刺激综合征发生率及周期取消率较低,其治疗也更经济。因此,拮抗剂方案可以考虑作为PCOS患者超促排卵的首选方案。 Abstract:ObjectiveTo compare the clinical efficacy and safety of GnRH-a long regimen and antagonist regimen in PCOS patients. MethodsA total of 240 PCOS patients requiring COH treatment were included. The patients were randomly divided into 2 groups, with 120 cases in each group. A group was treated with GnRH-a long program, and B group was treated with antagonist regimen. The clinical outcomes of the two groups were compared. ResultsIn terms of clinical efficacy, the number of oocytes obtained and the estrogen level at HCG days of the antagonist regimen group were significantly lower than the GnRH-a long regimen group (P<0.05). The Gn total dose and Gn starting dose of the antagonist regimen group were significantly lower than the GnRH-a long regimen group (P<0.01). The difference of high quality embryo rate and pregnancy rate between the two groups was not significant (P>0.05). The antagonist regimen group had an obviously OHSS incidence and cycle cancellation rate,the difference was significant (P<0.05). ConclusionThere is no significant difference between the two regimens. The antagonist regimen group has an obviously OHSS incidence and cycle cancellation rate. Its treatment is more economical. Thus, the antagonist regimen may be considered as the preferred COH regimen in PCOS patients. -
表 1 两组患者临床资料的比较(n=120,Mean±SD)
分组 年龄(岁) BMI LH(U/L) FSH(U/L) 睾酮(ng/dL) 窦卵泡计数(n) GnRH-a长方案组 28.9±3.6 24.6±4.1 9.4±4.2 6.1±1.6 47.4±20.1 26.0±8.8 拮抗剂组 29.1±3.5 24.4±3.7 9.5±3.7 5.9±1.8 48.6±19.5 27.2±9.3 t 0.436 –0.406 0.196 –0.91 0.469 1.027 P 0.656 0.693 0.918 0.354 0.628 0.307 LH:基础促黄体生成素;FSH:卵泡刺激素. 表 2 两组患者药物使用情况的比较(n=120,Mean±SD)
分组 Gn启动剂量(U) Gn总剂量(U) Gn使用时间(d) GnRH-a长方案组 156.6±37.6 1816.7±537.8 11.6±3.6 拮抗剂组 131.4±30.5 1550.5±462.7 10.8±4.3 t –5.702 –4.11 –1.563 P 0.000 0.001 0.103 表 3 两组患者促排卵情况的比较(n=120,Mean±SD)
分组 hCG日LH(U/L) hCG日E2(pg/mL) hCG日P(pg/mL) hCG日子宫内膜厚度(cm) 获卵数(n) GnRH-a长方案组 1.9±0.9 5546.7±1253.8 1.1±0.5 1.09±0.14 16.9±5.4 拮抗剂组 2.2±1.0 3688.3±1103.0 1.0±0.4 1.06±0.12 15.3±5.0 t 1.628 –12.191 –1.711 –1.782 –2.382 P 0.101 0.000 0.084 0.079 0.019 表 4 两组患者临床结局的比较(n=120,%)
分组 MⅡ卵率 受精率 优质胚胎率 周期取消率 妊娠率 异位妊娠率 流产率 OHSS发生率 GnRH-a长方案组 85.75(1739/2028) 61.05(1238/2028) 46.8(601/1284) 21.7(26/120) 56.4(53/94) 3.77(2/53) 11.32(6/53) 8.3(10/120) 拮抗剂组 85.04(1543/1836) 58.77(1079/1836) 45.9(539/1174) 11.7(14/120) 50.5(52/103) 1.92(1/52) 7.69(4/52) 2.5(3/120) χ2 2.198 0.165 0.198 4.32 0.687 0.324 0.401 4.855 P 0.122 0.695 0.642 0.045 0.351 0.526 0.436 0.039 -
[1] Harris HR, Terry KL. Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review[J]. Fertil Res Pract, 2016, 2(1): 14-22. doi: 10.1186/s40738-016-0029-2 [2] Azziz R. New insights into the genetics of polycystic ovary syndrome[J]. Nat Rev Endocrinol, 2016, 12(2): 74-5. doi: 10.1038/nrendo.2015.230 [3] 陈婷婷, 傅 萍, 邢 佳, 等. 多囊卵巢综合征发病机制的影响因子研究[J]. 中国优生与遗传杂志, 2016, 24(11): 122-5. [4] Sigala J, Sifer C, Dewailly D, et al. Is polycystic ovarian morphology related to a poor oocyte quality after controlled ovarian hyperstimulation for intracytoplasmic sperm injection? Results from a prospective, comparative study[J]. Fertil Steril, 2015, 103(1): 112-8. doi: 10.1016/j.fertnstert.2014.09.040 [5] 徐海静, 孙 赟. 控制性超促排卵中卵巢低反应的治疗策略及其进展[J]. 生殖与避孕, 2014, 34(10): 858-64, 874. doi: 10.7669/j.issn.0253-357X.2014.10.0858 [6] 陈圆辉, 徐晓航. 多囊卵巢综合征患者控制性促排卵策略研究进展[J]. 国际生殖健康/计划生育杂志, 2015, 34(2): 148-52. [7] 朱晓秋. 多囊卵巢综合征临床特征分析[J]. 中国实用医药, 2017, 12(3): 77-8. [8] Jesus Vazquez M, Romero-Ruiz A, Tena-Sempere M. Roles of leptin in reproduction, pregnancy and polycystic ovary syndrome: consensus knowledge and recent developments[J]. Metabolism, 2015, 64(1): 79-91. doi: 10.1016/j.metabol.2014.10.013 [9] 方宝平, 高雅琼, 李伟莉. 多囊卵巢综合症所致不孕症临床研究进展[J]. 中医药临床杂志, 2015, 27(10): 1489-92. [10] 李艳茹. 多囊卵巢综合症所致不孕症的临床治疗分析[J]. 实用妇科内分泌杂志: 电子版, 2016, 3(7): 83-5. [11] 李尚为. 多囊卵巢综合征的促排卵治疗[J]. 中国计划生育和妇产科, 2014, 6(6): 12-5. doi: 10.3969/j.issn.1674-4020.2014.06.04 [12] 魏代敏, 潘 烨, 石玉华. 多囊卵巢综合征辅助生殖治疗策略的优化[J]. 中华妇产科杂志, 2018, 53(1): 58-61. doi: 10.3760/cma.j.issn.0529-567x.2018.01.014 [13] 杨 芳, 杨蕴洁, 潘家坪, 等. 卵泡微环境改变对多囊卵巢综合征患者体外受精-胚胎移植的影响[J]. 同济大学学报: 医学版, 2014, 35(6): 54-8. [14] Lin J, Wang PY, Zhao JZ, et al. Outcomes of in vitro fertilization cycles among patients with polycystic ovary syndrome following ovarian puncture for in vitro maturation[J]. Int J Gynaecol Obstet, 2016, 135(3): 319-23. doi: 10.1016/j.ijgo.2016.06.027 [15] Sheng Y, Lu G, Liu J, et al. Effect of body mass index on the outcomes of controlled ovarian hyperstimulation in Chinese women with polycystic ovary syndrome: a multicenter, prospective, observational study[J]. J Assist Reprod Genet, 2017, 34(1): 61-70. doi: 10.1007/s10815-016-0830-1 [16] Balkan M, Kalkanli S, Akbas H, et al. Development of superovulation program and heterologous in vitro, fertilization test assessment in hamsters[J]. J Genet Couns, 2013, 8(6): 241-6. [17] 杨丽娟, 李 洁, 王 玫, 等. 不同促排卵方案对多囊卵巢综合征患者子宫及卵巢血流的影响[J]. 中国现代医学杂志, 2015, 25(23): 76-81. doi: 10.3969/j.issn.1005-8982.2015.23.015 [18] 孙 丽, 王李艳, 蔡柳洪, 等. 拮抗剂方案在卵巢高反应患者中的安全性探讨[J]. 中华生殖与避孕杂志, 2018, 38(3): 238-40. [19] 王晓琰. 多囊卵巢综合征患者不同超促排卵方案妊娠结局比较分析[D]. 济南: 山东大学, 2016. [20] 吴重聪, 杨桂艳, 阮永铭, 等. 长效GnRH-a长方案在年轻患者COH中应用优势的探讨[J]. 中国医学创新, 2014, 11(29): 7-9, 10. [21] 赵梓彤, 刘冬娥. 多囊卵巢综合征GnRH-a长方案卵巢慢反应相关因素分析[J]. 中国实用妇科与产科杂志, 2016, 32(10): 1006-11. [22] 张 燕, 包俊华, 俞喜凤, 等. 拮抗剂方案在IVF-ET患者中的临床应用及成本效果比[J]. 宁夏医学杂志, 2015, 37(9): 798-801. [23] 罗 璐, 陈明晖, 贾梦希, 等. GnRH拮抗剂方案在体外受精-胚胎移植周期中自发排卵风险的大样本量回顾性研究[J]. 中华妇产科杂志, 2016, 51(5): 352-6. doi: 10.3760/cma.j.issn.0529-567x.2016.05.006
计量
- 文章访问数: 1774
- HTML全文浏览量: 647
- PDF下载量: 10
- 被引次数: 0